ALNY

#336
Alnylam Pharmaceuticals, Inc.
339.41 USD
+1.92%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
339.41
339.41
Intervallo Annuale
225.84
495.55
Variazione giornaliera
+1.92%
Variazione Mensile
+9.06%
Variazione di 6 mesi
-27.66%
Variazione Annuale
+41.50%
Chiusura Precedente
333.00
Apertura
339.41
Bid
Ask
Minimo
339.41
High
339.41
Volume
197
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
  • Market Capitalization 45.01 B
  • Employee 2 500
  • Founded 2002
  • CEO Yvonne Greenstreet
  • Website www.alnylam.com
  • Headquarter Massachusetts, United States
  • FIGI BBG000BFGNJ5
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
170.67
Rapporto prezzo/fatturato
14.42

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Notizie